Heat Biologics is a biopharmaceutical company headquartered in Morrisville, NC, and has operations in San Antonio, TX. The company has a proprietary gp96 platform to activate immune responses against pathogenic or cancer antigens. The lead product, HS-110, is designed to leverage gp96 to stimulate a patient’s own T cells and is currently in phase II clinical trial for non–small cell lung cancer treatment. Heat Biologics has launched a program in collaboration with the University of Miami to develop a vaccine designed to protect against COVID-19.